Expending in situ vaccination in a second treated site improve the treatment. (A-B) Six- to 8-week-old BALB/C mice were implanted with 5 × 106 A20 cells on both flanks. One tumor was used as injection site and the other was monitored for systemic effect. Mice were treated with IT injection of 5 μg STINGa and SC injection of 50 μg anti-GITR. Mice were treated every other day 3 or 9 times. (A) Schedule of injections. (B) Growth curve of the treated and nontreated tumor. Data represent 1 experiment with 10 mice per group. (C-D) Six- to 8-week-old BALB/C mice were implanted with 5 × 106 A20 cells at 3 sites on the abdomen. Two tumors were used as injection site; the tired 1 was monitored for systemic effect. Mice were treated with IT injection of 1 μg STINGa and SC injection of 10 μg anti-GITR antibodies. One group of mice was treated every other day 3 times in the tumor 1. A second group of mice was treated 3 times every other day in tumor 1 and then received another 3 injections every other day in the second tumor. (C) Schedule of the injection. (D) Growth curve of the 3 tumors and survival of the mice. Data represent 1 experiment with 10 mice per group. Error bars are SEM. Statistical significance of tumor growth was calculated using 2-way ANOVA. Survival significance was calculated using Mantel-Cox. *P < .05; ***P < .001.
